Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ergocalciferol Effect on Mucin-1 in ADTKD-MUC1
NCT03747523Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of vitamin d in autosomal dominant tubulointerstitial kidney disease (ADTKD) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Plasma mucin-1 levels at 3 days. Started Mar 2019; status: completed.
02
Drugs
vitamin d
03
Conditions
autosomal dominant tubulointerstitial kidney disease (ADTKD)
Beyond the preview
Go deeper on NCT03747523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747523.